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Abstract
Background—Tumour necrosis factor alpha (TNFα) is a pro-inflammatory cytokine implicated in
atherosclerotic plaque formation. We investigated whether circulating TNFα is prospectively
associated with myocardial infarction (MI) or stroke in the older general population, independently
of established cardiovascular risk factors and other inflammatory markers related to CHD risk.
Methods—We measured baseline TNFα concentrations in stored serum samples of 362 incident
MI and 299 incident stroke cases and controls (2 per case, frequency matched by age, gender and
town) who were ‘nested’ in parallel prospective studies of 4252 men and 4286 women aged 60–79
years assessed in general practices in 24 British towns in 1998–2000 and followed up for an average
7 years for fatal and non-fatal MI and stroke.
Results—TNFα levels were 11.4% (95% CI 9.5, 13.3%) higher among MI cases than controls;
geometric mean 1.84 pg/mL compared to 1.63 pg/mL, p (difference) < 0.001. Participants in the top
third of baseline TNFα levels had an age-adjusted odds ratio (OR) for MI of 1.75 (95%CI 1.22, 2.49)
compared with those in the bottom third, which was reduced to 1.47 (95%CI 1.01, 2.14) after
adjustment for established cardiovascular risk factors. However, further adjustment for C-reactive
protein and interleukin-6 abolished the association OR 1.33 (95% CI 0.91, 1.66) and the linear trend.
Excluding subjects with pre-existing CVD did not materially affect results. No significant association
between TNFα and stroke was observed.
Conclusions—This study suggests that TNFα is not a strong independent risk marker for MI, and
is not associated with risk of stroke.
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TNFα, tumour necrosis factor alpha; MI, myocardial infarction; CVD, cardiovascular disease; CHD,
coronary heart disease; OR, odds ratio; IQR, inter-quartile range; CI, confidence interval; CRP, C-
reactive protein; IL-6, interleukin-6; BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; t-PA, tissue plasminogen activator; LR, likelihood ratio
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1 Introduction
Inflammation is important in the development and rupture of atherosclerotic lesions leading to
cardiovascular disease (CVD) events [1]. Population-based prospective studies report
associations between circulating acute phase inflammatory markers and CHD (coronary heart
disease) [2,3] and stroke [4]. Evidence is accumulating that pro-inflammatory cytokines (e.g.
interleukin 6 [IL-6]) are related to CHD risk [5]. Tumour necrosis factor alpha (TNFα) is a
pro-inflammatory cytokine important in initiating inflammatory responses [6]. Human studies
and animal models implicate TNFα in atherosclerotic plaque formation [7,8]. TNFα is
produced by macrophages, foam cells and mast cells (among others), promotes cellular
infiltration of the plaque and stimulates production of other cytokines which increase plaque
instability leading to thrombus formation [9].
Higher circulating levels of TNFα might be expected to be associated with increased CHD and
stroke risks based on experimental evidence, but epidemiologic evidence is inconsistent. Some
[10–12] but not all [13] cross-sectional data indicate positive associations between TNFα and
degree of atherosclerosis or level of prevalent CVD, and some studies of secondary CHD report
null findings [13,14]. There are few prospective studies of healthy individuals [11,12], and
they include fewer than 300 cases of hard CHD endpoints [11–13,15]. Some studies report
positive associations between TNFα and primary CHD risk [11,12]. Even fewer studies of
TNFα and stroke exist, the largest (n = 591 cases of recurrent stroke) reported positive
associations between TNFα and stroke [16], although findings for primary stroke risk have
been null [11,17]. Considerable uncertainty remains about the strength of association of
TNFα with risk of MI and stroke in generally healthy population cohorts.
We investigate associations between serum TNFα and risk of MI and stroke in two large parallel
prospective population-based studies of older adult men and women, and examine whether
associations are independent of established cardiovascular risk factors and inflammatory
markers implicated in cardiovascular risk.
2 Methods
In 1998–2000, 4252 men from one General Practice in each of 24 British towns participating
in a prospective study of CVD were followed up at age 60–79 years (response rate 77%)
[18]. In 1999–2001, a parallel study of 4286 women of the same age and in the same Practices
was established, with the addition of one town (Bristol) [19]. Near identical protocols for the
collection of data were used in both studies. Nurses made physical measurements, recorded an
electrocardiogram and collected fasting venous blood samples. Serum was stored at ≤−70 °C
for subsequent analysis. Participants were followed up for all cause mortality and
cardiovascular morbidity, for between 6.25 and 8.5 years with a loss of <2%. Fatal cases were
ascertained through National Health Service Central Registers using death certificates (ICD-9
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codes 410–414) for MI and (ICD-9 codes 430–438) for stroke, indicating deaths with
cerebrovascular disease as the underlying cause. Diagnosis of non-fatal MI or stroke was based
on reports from General Practitioners and reviews of General Practice records, and was in
accordance with World Health Organisation criteria [18,20]. Participants completed detailed
questionnaires about previous illnesses including MI or stroke, and lifestyle including cigarette
smoking, alcohol consumption and physical activity. Own longest-held occupation (or
husband's occupation for married, divorced and widowed women) was coded using the
Registrar General's classification. Town of residence was recorded for women in 1998–2000
and for men at the start of their follow-up in 1978–80. Weight, height and seated blood pressure
were measured and fasting blood samples provided for the measurement of cholesterol,
triglycerides and haemostatic and inflammatory markers [5,18,19,21]. All subjects provided
written informed consent to the investigation, and the ethical approval was provided by relevant
Local Research Ethics Committees.
We established a nested case–control study using all 390 MI cases occurring between
examination (1998–2000) and June 2006 in men and between examination (1999–2001) and
September 2007 in women. A total of 780 controls “frequency matched” to cases on town of
residence, gender and age in 5-year bands were randomly selected from survivors free from
incident CHD at the end of follow-up. Similarly a separate nested case–control study of 324
cases of stroke and 648 controls was established. Numbers of MI and stroke cases were
constrained by the numbers of relevant events, so two controls per case were used to increase
statistical power and precision of estimates of relative risks between TNFα, MI and stroke as
well as with other CVD risk factors. In the sample with complete data, there were 362 MI cases,
from which we would have had 80% power to detect a relative risk of 1.59 in the top tertile of
TNFα compared to the bottom tertile, at the 5% statistical significance level. From 299 cases
of stroke we would have had 80% power to detect a relative risk of 1.68 in the top tertile of
TNFα compared to the bottom tertile at the 5% statistical significance level, assuming 2 controls
per case.
TNFα (pg/mL) was measured from stored frozen serum samples using a commercially
available high-sensitivity ELISA (R&D systems, Abingdon, UK) by an investigator blinded
to case–control status of the samples. The coefficient of variation was 8.4% intra-assay and
12.5% inter-assay. In 158 men from two towns, TNFα was measured in samples obtained both
in 1996 and in 2000 to enable intra-individual comparisons over time (regression dilution)
[22].
2.1 Statistical methods
Highly skewed variables were natural log transformed. Means and standard deviations of
baseline characteristics of cases and controls aged 60–79 years were calculated. Continuous
variables were adjusted for gender, baseline region of residence and age at examination.
Distributions of categorical variables were examined. Tertiles of TNFα were defined in the MI
control sample. Associations between TNFα tertiles and covariates were examined using one-
way ANOVA. Unmatched logistic regression analyses were used to examine associations
between TNFα tertiles and MI. Models were first adjusted for gender, age and region. Further
adjustments for cardiovascular risk factors (selected a priori) were fitted as continuous
variables except for; smoking (current, ex or never), alcohol use (1–2 drinks/day or other)
physical activity (more or less than 3 h of moderate/vigorous activity per week), and history
of diabetes (present or absent).
For MI, regression models were first adjusted for glucose and insulin (both natural log
transformed) and then for novel risk factors which are consistently associated with CHD (log
transformed C reactive protein (CRP) and IL-6). For stroke, adjustments were made for CRP
and IL-6. Linear regression was used to model the association between risk of MI (or stroke)
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and continuous TNFα both as linear and log2 transformation (to assess the effect of a doubling
of TNFα level). Gender and age differences in the TNFα-CVD associations were tested using
likelihood ratio (LR) tests for interactions. All reported p-values are 2-sided. Sensitivity
analyses excluded participants with pre-existing CVD (self-report of MI or stroke at any
questionnaire between 1978–80 and 1998–2000 in men and in 1999/2000 questionnaire in
women).
The authors had full access to the data and take responsibility for its integrity. All authors have
read and agree to the manuscript as written.
3 Results
3.1 Baseline characteristics
For the MI case–control groups, data were available for 362 of 390 cases (267 men and 95
women, mean age 70.9 years) and for 698 of 780 controls. Cases differed from controls in
having higher prevalence of pre-existing CVD and diabetes (Table 1). Cases had higher
prevalence of smokers, fewer drinkers of 1–2 units of alcohol/day and fewer physically active
participants (all p < 0.05). They had higher systolic blood pressure (SBP) and lower forced
expiratory volume (FEV1) but similar body mass index (BMI) and diastolic blood pressure
(DBP). Cases had less favourable lipid and inflammatory markers. Geometric mean TNFα
level was 11.4% (95% CI 9.5, 13.3%) higher in MI cases than controls; 1.84 pg/mL (IQR 1.29,
2.42) compared to 1.63pg/mL (IQR 1.19, 2.18) p (difference) <0.001.
TNFα data were available for 299 of 324 stroke cases and 587 of 648 controls. Mean age of
cases was 71.3 years, and 63% were male. Cases had higher prevalence of pre-existing CVD,
diabetes and smokers than controls (all p < 0.05). They had higher blood pressure and lower
FEV1 but similar BMI. Cases had lower total cholesterol and higher IL-6, fibrinogen and white
blood cell count (although not CRP). Differences between cases and controls were less marked
than in the MI study population. TNFα levels were slightly higher among the stroke cases than
controls 1.88 pg/mL (IQR 1.28, 2.34) compared to 1.75 pg/mL (IQR 1.32, 2.36) p = 0.079
(Table 2).
3.2 Baseline correlates of TNFα
Table 3 presents associations between TNFα and potential confounders across thirds of the MI
control population (the larger control population). Increasing TNFα levels were associated with
female gender, but not with age or behavioural factors. Increasing TNFα was associated with
higher BMI, triglyceride, insulin and glucose (borderline) and lower HDL. TNFα was also
positively associated with CRP, IL-6, fibrinogen, white blood cell count, plasma viscosity,
coagulation factor VIII, D-dimer, von Willebrand factor (vWF) and tissue-plasminogen
activator (t-PA). Not all correlations between natural log TNFα and covariates reached levels
of conventional statistical significance (p < 0.05), those that did reach significance were all of
moderate magnitude r < 0.25 (e.g. r = 0.17, (p < 0.05) for CRP and r = 0.16, (p < 0.05) for
IL-6; r = 0.20 (p < 0.05) for plasma viscosity). Similar associations were observed in the stroke
control population (data not shown).
3.3 Association of TNFα with risk of MI
Table 4 summarizes associations between MI and tertiles of TNFα. Model 1 was adjusted for
gender, age and region of residence; the odds ratio (OR) for MI associated with the highest
compared to the lowest TNFα tertile was 1.75 (95%CI 1.22, 2.49) and there was a significant
linear trend in ORs across the tertiles (p = 0.002). After adjustment for established, behavioural
and metabolic cardiovascular risk factors, the OR was attenuated to 1.44 (95%CI 0.99, 2.11)
but the linear trend remained (Table 4). Adjustment for CRP and IL-6 attenuated the OR; 1.33
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(95% CI 0.91, 1.96) and abolished the linear trend. A doubling of TNFα level was associated
with increased OR for MI: 1.34 (95%CI 1.11, 1.60), which was reduced on adjustment for
established and metabolic risk factors, and completely attenuated by adjustment for
inflammatory markers. There was no evidence that associations between MI and tertiles of
TNFα varied by gender or age (LR test p = 0.101, p = 0.972 respectively). Likewise, interactions
were not observed for log2 TNFα and gender or age (LR test p = 0.684, p = 0.720 respectively).
Repeating analyses excluding 180 participants with pre-existing CVD, produced similar
results, although point estimates were wider due to loss of power and estimates were further
attenuated by adjustments, eliminating the trend in CHD.
3.4 Association of TNFα with risk of stroke
No significant associations between TNFα and stroke were observed in multivariate models
(Table 5). OR for stroke associated with top compared to bottom TNFα tertile was 1.12 (95%
CI 0.75, 1.66). There was no evidence of an interaction between gender and TNFα on stroke
(LR test p = 0.319), or age (LR test p = 1). There was not evidence of an association between
continuous TNFα and stroke; OR for doubling of TNFα 1.15 (95%CI 0.95, 1.39). Excluding
133 participants with prior CVD confirmed main analysis results.
3.5 Extent of regression dilution effect
Using Rosner's method [23], a regression dilution ratio of 0.25 (95%CI 0.15, 0.35) for TNFα
was calculated in 158 men with TNFα levels measured 4 years apart [22].
4 Discussion
In this, the largest prospective population-based study reported to date on serum TNFα levels
and risk of CVD, higher serum TNFα levels were associated with elevated MI risk in older
adults over a 7-year period. However, the association was partly attenuated by established and
metabolic risk factors, and reduced to non-significance by adjustment for circulating
inflammatory markers associated with CHD: CRP [2,4] and IL-6 [5]. However, TNFα was not
associated with risk of stroke.
4.1 Comparison with previous studies
TNFα was positively associated with some established risk factors: BMI and inversely with
HDL as reported in a cross-sectional study [24], but associations were not observed with total
cholesterol or blood pressure as seen in some but not all other studies [10,24]. TNFα is reported
to be an adipokine and is associated with metabolic processes [25,26], so positive associations
between TNFα and BMI, glucose and insulin observed here were expected. Associations
between TNFα and other “downstream” inflammatory markers which are emerging risk
predictors (fibrinogen, CRP, white cell count, plasma viscosity, vWF, Factor VIII, t-PA and
D-dimer) were modestly positive, similar to other reports [11,24] and unlikely to result in
collinearity. Higher TNFα among females was unexpected, but may be because women in this
study were post-menopausal [24].
The magnitude of the positive association of TNFα with MI adjusted for established risk factors
fits with other findings [11,12]. To deal with the different cut-points for TNFα tertiles between
studies, the association between continuous TNFα and MI risk was examined. The adjusted
OR for log10 TNFα in our study (1.18 (95%CI 1.00, 1.39) was very similar to association
reported elsewhere: RR 1.22 (1.04, 1.43) and their RR for stroke was also null, like our study
[12]. The Finnish study (of younger adults) reported non-linearity in the elevated risks of MI
and total mortality: men in the three highest quartiles of TNFα (>0.75 pg/L) had similarly raised
HR for MI 2.21 (95%CI 1.18–4.14) compared to the lowest quartile [12]. However in our study,
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the highest TNFα tertile (>1.89 pg/mL) had the most elevated odds ratio and linear trends were
observed across the tertiles. Finally, the lack of association between TNFα and stroke is
consistent with a recent study in the elderly at risk [17]. Our study confirms this finding in a
generally healthier population of older people.
4.2 Strengths and weaknesses
This is the largest study of TNFα, CHD and stroke; it includes more events than previous
prospective population-based studies, has a clinically relevant follow-up, and includes both
genders. The data add to the literature because few other studies report prospective data about
TNFα and subsequent risk of either MI [11,12,27,28] or stroke [11] in generally healthy
populations. The study population is representative of gender, social background and
geographical variation across the UK. This study benefits from validated data about MI and
stroke events collected from GP practices using standardized procedures and then individually
verified for accuracy. The validity of this procedure has been previously reported [29]. The
study also has comprehensive data on established and novel cardiovascular risk factors.
TNFα levels were measured blind to case status, using standard laboratory protocols on well-
preserved samples. The distributions of TNFα were similar to age-specific reference ranges
[24]. Patterns of association between TNFα and cardiovascular risk factors were similar to
other studies. Although a single measure of TNFα per subject was available, measurement of
intra-individual variability over 4 years in a subsample of 158 men is a strength [22].
4.3 Interpretation of results
This study suggests that associations between TNFα and MI are modest, although the high
intra-individual variability in TNFα levels measured 4 years apart, suggests lower long-term
biological stability of TNFα (in terms of expression) than other risk factors [22]. The low
regression dilution ratio (0.25) is similar to that of another pro-inflammatory cytokine IL-6,
suggesting that, like IL-6, the association of TNFα with incident CHD may be underestimated
in studies with single measurements [5]. The modest associations observed between TNFα and
MI are unlikely to be only due to the wide range of established biological, social or behavioural
risk factors we measured (since these were adjusted for in regression models), or due to
participants having pre-existing CVD: sensitivity analyses excluded such participants.
Associations between TNFα and MI were independent of insulin and glucose, fitting with data
from a prospective study of diabetic women, where CHD risks were elevated independent of
hyperglycemia [27]. Associations between TNFα and MI were attenuated particularly when
CRP and IL-6 (separately or together) were included in multivariate analyses, whilst CRP and
IL-6 remained independently associated with MI, suggesting that each could be important
pathways from TNFα to MI risk. Most studies of TNFα and MI have not adjusted for other
inflammatory markers. One study reported that adjustment for CRP, partially attenuated the
association between TNFα and CHD but abolished the association with total mortality,
however that study did not include IL-6 [11]. Adjusting for any inflammatory markers may be
over-adjustment in terms of aetiology, since TNFα is thought to act synergistically with IL-6
and IL-1, upstream of the acute phase response [30]. However in our study, no statistical
interaction between TNFα and IL-6 on MI or stroke was observed. Hence in biological terms,
the association of “downstream” acute-phase reactants (such as CRP, fibrinogen or white cell
count) with CVD endpoints could be primarily due to increased levels of circulating TNFα,
IL-6 and potentially other pro-inflammatory cytokines [5,7,8]. The attenuation of associations
of TNFα with outcome confirms findings in a recurrent stroke study, that a profile of raised
inflammatory markers (rather than any specific independent inflammatory marker) is
associated with vascular risk [16]. Hence TNFα does not add much to other inflammatory
markers in predicting CHD risk. For example, CRP which probably has more robust
associations with CHD risk, may not much improve risk prediction [4]. Overall, due to
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relatively modest associations with CHD risk, a relatively high degree of regression dilution,
and confounding by generalized inflammation, TNFα is unlikely to be a clinically useful risk
biomarker, although this does not diminish a potential role in CHD aetiology.
4.4 Conclusions
Our study provides further evidence that TNFα is associated with a modestly elevated risk of
MI, after adjustment for established cardiovascular risk factors, although this association is not
independent from inflammatory markers CRP or IL-6. Associations with stroke were not
observed. The modest association with MI may give insights into the process of MI risk, but
TNFα is unlikely to be a clinically useful risk marker for identifying patients at risk of CHD.
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Table 1
Baseline characteristics (age 60–79) of the MI case and control populations: mean
(SD) unless otherwise specified.a.
MI cases (n = 362) MI controls (n = 698) Difference (p-value)
Demographic/questionnaire
 Age (years) 70.91 (5.48) 70.80 (5.44) Matched
 Male, n (%) 267 (73.6) 512 (73.1) Matched
 Northern region of residence, n (%)b 150 (41.0) 286 (41.4) Matched
 Non-manual occupation, n (%)b 152 (44.4) 319 (47.9) 0.298
 Prior evidence of MI or stroke, n (%) 107 (29.6) 117 (16.8) <0.001
 History of diabetes, n (%) 55 (20.6) 55 (10.7) <0.001
 1–2 alcoholic drinks/day, n (%) 126 (37.8) 299 (46.4) 0.010
 Current smoker, n (%) 75 (20.72) 93 (13.3) 0.004
 Physical activity (inactive/occasional), n
(%)
231 (66.4) 391 (58.6) 0.016
Physical measurements
 Body mass index (kg/m2)c,d 27.11 (4.26) 27.02 (3.95) 0.728
 Systolic blood pressure (mmHg)c,d,e 153.94 (27.22) 148.55 (24.16) 0.001
 Diastolic blood pressure (mmHg)c,d,e 83.85 (12.07) 83.22 (11.52) 0.409
 FEV1 (L/min)
c,d,f 2.15 (0.55) 2.23 (0.60) 0.028
Lipids/metabolic markers
 Total cholesterol (mMol/L)c 6.24 (1.22) 6.08 (1.07) 0.027
 HDL cholesterol (mMol/L)c 1.31 (0.33) 1.41 (0.36) <0.001
 Triglyceride (mMol/L)c,e,g 1.80 (1.32, 2.40) 1.58 (1.14, 2.12) <0.001
 Insulin (mU/L)c,e,g 9.25 (5.57, 13.61) 7.85 (5.37, 11.07) <0.001
 Glucose (mMol/L)c,e,g 6.19 (5.36, 6.38) 5.84 (5.37, 6.12) <0.001
Inflammatory and haemostatic markers
 TNFα(pg/mL)c,g 1.84 (1.29, 2.42) 1.63 (1.19, 2.18) <0.001
 C-Reactive Protein (mg/L)c,g 2.41(1.08, 5.58) 1.77 (0.90, 3.60) <0.001
 IL-6(pg/mL)c,e,g 2.99 (1.89, 4.26) 2.43 (1.54, 3.47) <0.001
 Fibrinogen (g/L)c,e,g 3.47 (3.03, 3.98) 3.26 (2.85, 3.75) <0.001
 White cell count (^109/L)c,e,g 7.27 (6.01, 8.84) 6.80 (5.68, 7.98) <0.001
a
Case–control sample is maximum available.
b
Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c
Adjusted for gender, age at survey and region of residence (Scotland, North, Midlands and South).
d
Adjusted for nurse number.
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e
Adjusted for time of day.
f
Adjusted for height squared.
g
Analysed as natural log transformed variable, geometric mean (IQR) reported on original scale.
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Table 2
Baseline characteristics (age 60–79) of the stroke case and control populations:
mean (SD) unless otherwise specified.a.
Stroke cases (n = 299) Stroke controls (n = 587) Difference (p-value)
Demographic/questionnaire
 Age (years) 71.29 (5.32) 71.35 (5.24) Matched
 Male, n (%) 191 (63.4) 372 (63.9) Matched
 Northern region, n (%)b 108 (36.1) 219 (37.3) Matched
 Non-manual occupation, n (%)b 148 (54.8) 290 (52.9) 0.609
 Prior evidence of MI or stroke, n (%) 84 (28.1) 89 (15.2) <0.001
 History of diabetes, n (%) 31 (16.2) 37 (10.0) 0.030
 1–2 alcoholic drinks/day, n (%) 105 (38.6) 210 (38.5) 0.937
 Current smoker, n (%) 51 (17.1) 57 (9.7) 0.004
 Physical activity (inactive/
occasional), n (%)
196 (71.0) 377 (66.8) 0.223
Physical measurements
 Body mass index (kg/m2)c,d 27.05 (4.37) 27.12 (4.11) 0.814
 Systolic blood pressure (mmHg)c,d,e 154.10 (25.01) 149.13 (24.24) 0.005
 Diastolic blood pressure (mmHg)
c,d,e
84.84 (12.60) 82.36 (11.18) 0.003
 FEV1 (L/min)
c,d,f 2.09 (0.57) 2.24 (0.52) <0.001
Lipids/metabolic markers
 Total cholesterol (mMol/L)c 6.12 (1.22) 6.31 (1.17) 0.024
 HDL cholesterol (mMol/L)c 1.43 (0.40) 1.42 (0.36) 0.736
 Triglyceride (mMol/L)c,e,g 1.64 (1.10, 2.31) 1.69 (1.23, 2.29) 0.363
 Insulin (mU/L)c,e,g 8.53 (5.31, 12.02) 7.96 (5.03, 10.93) 0.159
 Glucose (mMol/L)c,e,g 6.05 (5.34, 6.19) 5.88 (5.32, 6.12) 0.085
Inflammatory and haemostatic markers
 TNFα (pg/mL)c,g 1.88 (1.28, 2.34) 1.75 (1.32, 2.36) 0.079
 C-Reactive protein (mg/L)c,g 2.12 (1.03, 4.44) 1.92 (0.91, 4.16) 0.239
 IL-6(pg/mL)c,e,g 2.83 (1.85, 4.01) 2.56 (1.64, 3.53) 0.026
 Fibrinogen (g/L)c,e,g 3.35 (2.95, 3.84) 3.28 (2.87, 3.75) 0.142
 White cell count (^109/L)c,e,g 7.22 (6.14, 8.56) 6.90 (5.74, 8.20) <0.001
a
Case control sample is maximum available.
b
Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c
Adjusted for gender, age at survey and region of residence (Scotland, North, Midlands and South).
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d
Adjusted for nurse number.
e
Adjusted for time of day.
f
Adjusted for height squared.
g
Analysed as natural log transformed variable, geometric mean (IQR) reported on original scale.
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Table 3
Association between TNFα (tertiles) and cardiovascular risk factors in the MI
control sample (n = 698).
Low (0.03–1.3) N = 233 Medium (1.31–1.88) N = 234 High (1.89–13.56) N = 231 Trend p-valuea
Demographic/questionnaire
 Age (years) 70.30 70.70 71.40 0.090
 Male, n (%) 171 (73.4) 184 (78.6) 157 (68.0) 0.034
 Northern region, n (%)b 96 (41.2) 94 (40.2) 96 (41.6) 0.951
 Non-manual occupation, n
(%)b
113 (51.6) 106 (47.5) 100 (44.6) 0.339
 Evidence of stroke, n (%) 20 (11.7) 17 (9.2) 25 (15.9) 0.165
 History of diabetes, n (%) 16 (9.4) 21 (11.4) 18(11.5) 0.773
 1–2 alcoholic drinks/day, n
(%)
102 (48.3) 107 (48.2) 90 (42.7) 0.407
 Current smoker, n (%) 33 (14.2) 23 (9.9) 37 (16.0) 0.131
 Physical activity (inactive/
occasional), n (%)
125 (56.3) 126 (55.5) 140 (64.2) 0.122
Physical measurements
 Body mass index (kg/m2)c,d 26.38 27.42 27.24 0.001
 Systolic blood pressure
(mmHg)c,d,e
148.59 149.33 147.66 0.757
 Diastolic blood pressure
(mmHg)c,d,e
83.04 82.81 83.81 0.065
 FEV1 (L/min)
c,d,f 2.27 2.23 2.17 0.240
Lipids/metabolic markers
 Total cholesterol (mMol/L)c 6.09 6.09 6.06 0.914
 HDL cholesterol (mMol/L)c 1.50 1.43 1.32 <0.001
 Triglyceride (mMol/L)c,e,g 1.44 1.59 1.71 <0.001
 Insulin (mU/L)c,e,g 7.28 7.64 8.67 0.004
 Glucose (mMol/L)c,e,g 5.71 5.88 5.94 0.056
Inflammatory and haemostatic markers
 C-Reactive Protein (mg/L)c,g 1.41 1.74 2.25 <0.001
 IL-6(pg/mL)c,e,g 2.20 2.33 2.80 <0.001
 Fibrinogen (g/L)c,e,g 3.16 3.26 3.37 0.012
 White cell count (^109/L)
c,e,g
6.61 6.64 7.14 0.003
 Plasma viscosity (mPa s)c,e 1.27 1.29 1.31 <0.001
 Factor VIII (IU/dL)c 141.35 138.52 148.09 0.005
 Fibrin D-dimer (ng/mL)c,g 80.74 91.18 118.99 <0.001
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Low (0.03–1.3) N = 233 Medium (1.31–1.88) N = 234 High (1.89–13.56) N = 231 Trend p-valuea
 von Willebrand factor (IU/dL)
c
139.61 142.16 157.31 <0.001
 t-PA (ng/mL)c,e 9.74 10.32 11.14 <0.001
a
Sample (n = 698) MI controls with TNFα value. Trend test adjusted for age, gender, region of residence.
b
Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c
Adjusted for age at survey and region of residence (Scotland, North, Midlands and South).
d
Adjusted for nurse number.
e
Adjusted for time of day.
f
Adjusted for height squared.
g
Geometric mean, p-value from ANOVA with ln (variable).
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Table 4
Odds ratio (95% CI) of MI in men and women with TNFα values in the higher
tertiles compared to the lower tertile of the distribution (n = 867).a.
TNFα MI cases MI controls OR (95% CI) with adjustments
Tertiles Model 1 Model 2 Model 3 Model 4
Range (pg/mL)
 1.89–22.90 128 186 1.75 (1.22, 2.49) 1.47 (1.01, 2.14) 1.44 (0.99, 2.11) 1.33 (0.91, 1.96)
 1.31–1.88 84 203 1.03 (0.71, 1.48) 0.99 (0.67, 1.44) 0.98 (0.67, 1.44) 0.94 (0.64, 1.39)
 0.03–1.30 77 189 1 1 1 1
Total 289 578 p = 0.002 p = 0.038 p = 0.049 p = 0.125
Continuous Model 1 Model 2 Model 3 Model 4
1 log2 (TNFα)b 289 578 1.34 (1.11, 1.60) 1.25 (1.03, 1.51) 1.23 (1.02, 1.49) 1.18 (0.97, 1.43)
Model 1 = age, gender and region.
Model 2 = model 1 + smoking, alcohol, physical activity, history of diabetes, BMI, SBP, DBP, TC, HDL.
Model 3 = model 2 + insulin + glucose.
Model 4 = model 3 + IL-6 + CRP.
a
Complete case analysis sample. Tertiles based on control group. p-value for test for trend over tertiles.
b
OR of MI per 1 log2 increase in log 2(TNFα), i.e. doubling of TNFα.
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Table 5
Odds ratio (95% CI) of stroke in men and women with TNFα values in the higher
tertiles compared to the lower tertile of the distribution (n = 722).a.
TNFα Stroke cases Stroke controls OR (5% CI) with adjustments
Tertiles Model 1 Model 2 Model 3
Range (pg/mL)
2.07–45.30 78 161 1.12 (0.75, 1.66) 1.15 (0.76, 1.74) 1.11 (0.73, 1.69)
1.40–2.06 80 155 1.19 (0.81, 1.75) 1.13 (0.75, 1.69) 1.11 (0.74, 1.66)
0.03–1.39 76 172 1 1 1
Total 234 488 p = 0.567 p = 0.516 p = 0.631
OR (95% CI)
Continuous Model 1 Model 2 Model 3
1 log2 (TNFα)b 234 488 1.15 (0.95, 1.39) 1.14 (0.93, 1.40) 1.13 (0.92, 1.38)
Model 1 = age, gender and region.
Model 2 = model 1 + smoking, alcohol, physical activity, history of diabetes, BMI, SBP, DBP, TC, HDL.
Model 3 = model 2 + IL-6 + CRP.
a
Complete case analysis sample. Tertiles based on control group. p-value for test for trend over tertiles.
b
OR of MI per 1 log2 increase in log 2(TNFα), i.e. doubling of TNFα.
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